Esophageal variceal bleeding
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) The subject voluntarily and signed the informed consent form for this trial; 2) patients with diagnosis of liver cirrhosis based on clinical manifestations, laboratory tests, imaging examinations or liver biopsy; 3) Symptoms related to acute variceal upper gastrointestinal bleeding, such as hematemesis/melena/hematochezia, etc. before or during hospitalization (regardless of previous bleeding history); 4) Patients with endoscopic confirmation of esophageal variceal bleeding; 5) hemodynamically stable patients before or after initial fluid resuscitation; 6) Age> 18 years old and < 75 years old.
Exclusion criteria
Exclusion criteria: 1) Endoscopic confirmation of non-simple esophageal variceal bleeding, such as gastric variceal bleeding or isolated gastric variceal bleeding, etc.; 2) tracheoesophageal fistula; 3) esophageal rupture; 4) Tumors of the pharynx, larynx, esophagus, stomach or upper respiratory tract; 5) esophageal stricture; 6) recent esophageal surgery; 7) pregnancy or breastfeeding; 8) Those who cannot be selected for any reason in the opinion of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of hemostasis at 5 days after treatment of acute esophageal variceal bleeding; | — |
Secondary
| Measure | Time frame |
|---|---|
| Characteristics of the patient population;Duration of the procedure;The stent is left in place;Rescue therapy such as blood transfusion and TIPS;Stent dwelling time;Rate of hemostasis at 6 weeks after treatment;Mortality at 5 days and 6 weeks after treatment;Child score and MELD score before and after stent treatment;Incidence of adverse events;Rebleeding rate;Endoscopic manifestations of varices before and after secondary prevention, rebleeding rate;Cost-effectiveness, e.g., length of hospital stay, hospitalization costs, total medical costs during follow-up; | — |
Countries
China
Contacts
Eastern Theater General Hospital